Prevalence and factors associated with sarcopenia in patients with rheumatoid arthritis

Torii, Mie; Hashimoto, Motomu; Hanai, Akiko; Fujii, Tomoyuki; Furu, Moritoshi; Ito, Hiromu; Uozumi, Ryuji; Hamaguchi, Masahide; Terao, Chikashi; Yamamoto, Wataru; Uda, Miyabi; Nin, Kazuko; Morita, Satoshi; Arai, Hidenori; Mimori, Tsuneyo

doi:10.1080/14397595.2018.1510565

Cited by 118 publications

(187 citation statements)

References 32 publications

Supporting

Mentioning

154

Contrasting

Unclassified

Order By: Relevance

“…Torii et al (12) described a higher prevalence of low muscle mass in RA patients (49%) in Japan, and similar findings were also found by two independent studies performed in RA patients from Morocco and Turkey (39.8% and 43.3%, respectively) (13,8). However, the rate of low skeletal muscle mass observed in our patients with RA was lower (27.8%), closer to that found in studies performed in Europe and in the United States, in which the reported rates of low muscle mass vary from 20% to 28.6% (7,10).…”

Section: Discussionsupporting

confidence: 64%

“…Muscle mass was estimated by DXA, computing the skeletal muscle index (SMI) according to the validated protocol described by Baumgartner et al (20). To calculate SMI, the skeletal muscle mass of the extremities (SMME) was first computed as the sum of the muscle mass of the four limbs obtained from DXA results, and then SMME was adjusted by height (meters squared) (SMI = SMME / height 2 ) (12). The result of this computation gives a value of SMI expressed in kg/m 2 .…”

Section: Body Composition Measurementsmentioning

confidence: 99%

“…Although the majority of the studies performed in RA patients conclude that the frequency of low skeletal muscle mass is higher than that observed in controls (6)(7)(8)(9)(10),the prevalence rates of myopenia in RA vary widely from 11% to 49% (11,12). A deteriorated skeletal muscle mass should be detected early and treated adequately in RA patients because low muscle mass may be associated with muscle weakness, impairment of functioning, and deteriorated health-related quality of life, among other adverse consequences (13,14,5).…”

Section: Introductionmentioning

confidence: 99%

“…The factors associated with low muscle mass in RA include the persistence of active disease with moderate to severe inflammation accomplished of increased acute phase reactants levels (12)(13)(14).…”

Section: Introductionmentioning

confidence: 99%

“…Nevertheless, to date, there is only limited and inconsistent information about the relation between low skeletal muscle mass and the type of drugs used for the treatment in RA (15,12,6,8,10,16).…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Treatment Failure with combined csDMARDs increases the risk of Low Muscle Mass in women with Rheumatoid Arthritis: a cross-sectional study

Ramírez-Villafaña

Rodriguez-Jimenez

Gámez-Nava

et al. 2020

Preprint

View full text Add to dashboard Cite

Background Low muscle mass (myopenia) is frequent in rheumatoid arthritis (RA) patients with a long-disease duration. Although, the use of combined therapy with conventional synthetic DMARDs (csDMARDs) is one of the main strategies observed in these patients; there is a lack of information if the failure to these therapies increases the risk of myopenia. Objective: To evaluate whether the treatment failure to combined therapy with conventional synthetic DMARDs is an independent risk factor for low skeletal muscle mass in women with RA. Methods This cross-sectional study compared 277 women with RA (cases) and 237 women from non-rheumatic population (controls). In RA patients, we assessed clinical, epidemiological, and therapeutic variables (identifying treatment failure to combined therapy with csDMARDs. The skeletal muscle index (SMI) was estimated by DXA. Low skeletal muscle mass was defined as SMI<5.45 kg/m2. Multivariate logistic regression analyses were used to a) evaluate whether RA is an independent risk factor of myopenia in comparison with non-rheumatic population and b) identify if treatment failure with csDMARDs is an independent risk factor of myopenia in RA. Results RA patients had a higher prevalence of low skeletal muscle mass than controls (27.8% vs. 15.6%, p=0.001). After adjusting for other factors, RA patients had higher risk of low skeletal muscle mass than controls (OR: 2.7, 95%CI:1.7 to 4.5). Risk factors of low muscle mass in RA patients; were: menopause (OR: 2.3, 95%CI: 1.2 to 4.6, p=0.02) and a failure to combined therapy with csDMARDs (OR: 2.4, 95%CI: 1.10 to 5.81, p=0.03). Conclusions Rheumatoid arthritis is associated with an increased risk of myopenia. Treatment Failure with conventional-synthetic DMARDs constitutes a strong risk factor for deteriorated skeletal muscle mass.

show abstract